Literature DB >> 17689098

HLA-G expression in malignant melanoma.

Vera Rebmann1, Stefan Wagner, Hans Grosse-Wilde.   

Abstract

Both, the expression of HLA-G (a non-classical HLA class I molecule) and the loss of classical HLA class I molecules enable tumor cells to evade from immunosurveillance of the host. Whereas HLA-G down-modulates the immune functions of all cells participating in the immune defence mechanisms, defects on HLA class I expression result in the resistance of tumor cells to cytotoxic T lymphocytes attacks. This contribution reviews the HLA-G expression pattern in malignant melanoma lesions, its correlation to the loss of classical HLA class I antigens, and new aspects of HLA-G regulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17689098     DOI: 10.1016/j.semcancer.2007.06.010

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  16 in total

Review 1.  Shedding light on melanocyte pathobiology in vivo.

Authors:  M Raza Zaidi; Edward C De Fabo; Frances P Noonan; Glenn Merlino
Journal:  Cancer Res       Date:  2012-03-15       Impact factor: 12.701

2.  Impact of HLA-G polymorphism on the outcome of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma.

Authors:  R Crocchiolo; O Ringden; J-O Bay; D Blaise; B Omasic; B Mazzi; C Picard; S Trinca; L Barkholt; J Peccatori; S Gregori; G Amodio; K Fleischhauer; F Ciceri; M Bregni
Journal:  Bone Marrow Transplant       Date:  2017-11-13       Impact factor: 5.483

Review 3.  HLA-G regulators in cancer medicine: an outline of key requirements.

Authors:  Ines Zidi; Nidhal Ben Amor
Journal:  Tumour Biol       Date:  2011-07-27

Review 4.  Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?

Authors:  Laurence Amiot; Soldano Ferrone; Hans Grosse-Wilde; Barbara Seliger
Journal:  Cell Mol Life Sci       Date:  2010-11-10       Impact factor: 9.261

5.  Low expression of human histocompatibility soluble leukocyte antigen-G (HLA-G5) in invasive cervical cancer with and without metastasis, associated with papilloma virus (HPV).

Authors:  Marcia C M Guimarães; Christiane P Soares; Eduardo A Donadi; Sophie F M Derchain; Liliana A L A Andrade; Tarsia G A Silva; Marcela K Hassumi; Renata T Simões; Fabiana A Miranda; Régia C P Lira; Janaina Crispim; Edson G Soares
Journal:  J Histochem Cytochem       Date:  2009-09-28       Impact factor: 2.479

6.  Synthetic HLA-G proteins for therapeutic use in transplantation.

Authors:  Joel LeMaoult; Marina Daouya; Juan Wu; Maria Loustau; Anatolij Horuzsko; Edgardo D Carosella
Journal:  FASEB J       Date:  2013-06-10       Impact factor: 5.191

7.  HLA-G, cytokines, and cytokine receptors in the non-aggressive basal cell carcinoma microenvironment.

Authors:  Andrezza Telles Westin; Luiz Gustavo Gardinassi; Edson Garcia Soares; João Santana Da Silva; Eduardo Antonio Donadi; Cacilda Da Silva Souza
Journal:  Arch Dermatol Res       Date:  2021-04-03       Impact factor: 3.017

Review 8.  Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association.

Authors:  Eduardo A Donadi; Erick C Castelli; Antonio Arnaiz-Villena; Michel Roger; Diego Rey; Philippe Moreau
Journal:  Cell Mol Life Sci       Date:  2010-11-24       Impact factor: 9.261

9.  Interferon-γ links ultraviolet radiation to melanomagenesis in mice.

Authors:  M Raza Zaidi; Sean Davis; Frances P Noonan; Cari Graff-Cherry; Teresa S Hawley; Robert L Walker; Lionel Feigenbaum; Elaine Fuchs; Lyudmila Lyakh; Howard A Young; Thomas J Hornyak; Heinz Arnheiter; Giorgio Trinchieri; Paul S Meltzer; Edward C De Fabo; Glenn Merlino
Journal:  Nature       Date:  2011-01-19       Impact factor: 49.962

10.  Case-control study of HLA-G promoter methylation status, HPV infection and cervical neoplasia in Curitiba, Brazil: a pilot analysis.

Authors:  Anna Gillio-Tos; Maria da Graça Bicalho; Valentina Fiano; Chiara Grasso; Valentina Tarallo; Laura De Marco; Morena Trevisan; Marinabarbaradesousa Xavier; Renata Slowik; Newton S Carvalho; Carlos A Maestri; Hadriano M Lacerda; Daniela Zugna; Lorenzo Richiardi; Franco Merletti
Journal:  BMC Cancer       Date:  2012-12-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.